Related Experiment Video
Updated: Aug 13, 2026
10:19
Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease
Published on: August 22, 2014
Regulatory issues in aging pharmacology
1Rinat Neuroscience Corporation, South San Francisco, California 94080, USA. hefti@rinatneuro.com
Aging Cell
|January 31, 2006
Summary
Future drugs may extend lifespan by targeting aging mechanisms, not just diseases. Developing these requires new strategies for safety, long-term studies, and regulatory approval, potentially using biomarkers.
Area of Science:
- Gerontology and drug development.
- Molecular mechanisms of aging.
- Regulatory science for longevity interventions.
Background:
- Current drug development focuses on treating diseases to extend lifespan.
- Aging research reveals potential to target aging pathways directly for lifespan extension.
- Existing regulatory frameworks are not designed for anti-aging therapeutics.
Purpose of the Study:
- To explore strategies for developing and regulating future drugs that target aging mechanisms.
- To address the challenges of high safety requirements and long study durations for longevity drugs.
- To propose pathways for the development and approval of aging-modulating therapeutics.
Main Methods:
- Review of current drug development and regulatory paradigms.
- Analysis of challenges posed by targeting aging in healthy populations.
- Proposal of two potential pathways for drug development and regulatory approval.
Main Results:
- Novel drugs targeting aging mechanisms require distinct development and regulatory strategies.
- High safety standards and extended clinical trials are necessary for longevity interventions.
- Biomarkers of aging could serve as surrogate endpoints in clinical studies.
Conclusions:
- Developing drugs that regulate aging requires new approaches beyond disease treatment.
- Public funding and biomarker-based trials are potential pathways for aging intervention research.
- Regulatory agencies need to establish guidance for longevity-enhancing drug development.
Related Concept Videos
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...